and fast
              pressure reduction, but significant side manifestations are not allowed
              use it in many patients and prolonged general purpose
              It was impossible. Creation of a carbonic anhydrase inhibitor for topical
              application that does not have systemic side effects and effectively
              lowering IOP, delayed for many years. It turned out that the decline
              the level of IOP can be achieved only if the blocked
              activity of not less than 99,9% of the enzyme. To achieve such an effect
              to rapid penetration of the dasg inside the eye and its high
              activity.

            

That is, the active substance was easily soluble
              in water for successfully overcoming the stroma of the cornea and aqueous humor
              chamber and at the same time is highly soluble in lipids, providing
              penetration through corneal epithelium. And all known inhibitors
              carbonic anhydrase did not have such svoystvami.Problemu managed
              solved with the creation of dorzolamida hydrochloride. Suppression
              anhydrase ciliary processes reduces the formation of watery
              Moisture anterior chamber.

            

As a result of decreased IOP. Reduction efficiency
              pressure during instillation dorzolamida hydrochloride 3 times a day
              ranges from 3 to 5 mm Hg. Art., and the effect lasts for
              long time use of the dasg. Instillation rarely 3
              times a day reduce the curative effects. Instillation of the dasg leads
              to penetration of the active substance in the blood, but its concentration
              in plasma is very low. In spite of this can not be
              exclude the occurrence of systemic side effects characteristic of
              carbonic anhydrase inhibitors and sulfonamides. Joint application
              dorzolamida hydrochloride with systemic carbonic anhydrase inhibitors
              not recommended.

            

an application with timolol and betaxolol
              any clinically significant adverse interactions are not established.
              The most common local side manifestations expressed in burning
              and discomfort after instillation. In rare cases, revealed a superficial
              Spot keratitis.